| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 76189-0535-60 | 76189-0535 | Ponatinib Hydrochloride | Iclusig | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 14, 2012 | Jul 26, 2020 | No Longer Used |
| 00078-0649-13 | 00078-0649 | Imatinib Mesylate | Gleevec | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 1, 2024 | In Use | |
| 59651-0546-30 | 59651-0546 | DASATINIB | DASATINIB | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 60505-3817-03 | 60505-3817 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
| 00003-0524-11 | 00003-0524 | Dasatinib | Sprycel | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 27, 2006 | In Use | |
| 00003-0527-11 | 00003-0527 | Dasatinib | Sprycel | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 27, 2006 | In Use | |
| 00378-2245-77 | 00378-2245 | imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2017 | In Use | |
| 68180-0390-09 | 68180-0390 | IMATINIB | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jul 8, 2019 | In Use | |
| 00003-0855-22 | 00003-0855 | Dasatinib | Sprycel | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 28, 2010 | In Use | |
| 00069-0193-01 | 00069-0193 | Bosutinib monohydrate, Bosutinib | BOSULIF | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 18, 2017 | In Use | |
| 70709-0156-14 | 70709-0156 | Dasatinib | PHYRAGO | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 22, 2025 | In Use | |
| 70771-1395-05 | 70771-1395 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 72205-0238-64 | 72205-0238 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 20, 2025 | In Use | |
| 67184-0533-02 | 67184-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 31722-0780-33 | 31722-0780 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 76189-0533-30 | 76189-0533 | Ponatinib Hydrochloride | Iclusig | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2015 | Jul 26, 2020 | No Longer Used |
| 60505-2900-03 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
| 76282-0790-58 | 76282-0790 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 14, 2025 | In Use | |
| 70710-1745-03 | 70710-1745 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 24338-0154-01 | 24338-0154 | Nilotinib | DANZITEN | 71.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 30, 2024 | In Use | |
| 43598-0602-30 | 43598-0602 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 51991-0376-90 | 51991-0376 | IMATINIB MESYLATE | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | Mar 31, 2023 | No Longer Used |
| 62332-0684-60 | 62332-0684 | DASATINIB | DASATINIB | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 11, 2025 | In Use | |
| 59651-0542-60 | 59651-0542 | DASATINIB | DASATINIB | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 60505-3801-07 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use |
Found 12393 results — Export these results
Home